On April 15, 2010
Genzyme’s Dilemma: Its Cheap Cancer Drug Wants to Cannibalize a Potential MS Blockbuster
Genzyme (GENZ)’s potential new treatment for multiple sclerosis may be too cheap, and the company could be looking for a way to raise the price if it wants to take maximum advantage of the hugely lucrative MS market. That’s the
…
0 Comments